Digest Network Come funziona
Network
/
Società
Gi
Non verificato

Gilead Sciences, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteSanità

130 comunicati stampa

Guarda tutti i comunicati
12/06/2026
Industria
Salute
HIV, AIDS e malattie autoimmuni
Sanità
Farmaceutica
Biotecnologia
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
11/06/2026
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
08/06/2026
Multimedialità
Industria
Scienza
Sanità
Farmaceutica
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Igiene alimentare
Salute
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
05/06/2026
Biotecnologia
HIV, AIDS e malattie autoimmuni
Sanità
Salute
Farmaceutica
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
04/06/2026
Multimedialità
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Mercato azionario
Industria
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
02/06/2026
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
27/05/2026
Biotecnologia
Sanità
Salute
Farmaceutica
Medicina - Varie
Eventi
Industria
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
22/05/2026
Industria
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
HIV, AIDS e malattie autoimmuni
Sanità
Medicina - Varie
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
22/05/2026
Industria
Oncologia
Igiene alimentare
Salute
Sanità
Farmaceutica
Biotecnologia
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
21/05/2026
Eventi
Fiere
Industria
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0